BEAM250117P19000
- 0.10
- 0.000.00%
Beam Therapeutics Newsroom
Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $75
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN), Beam Therapeutics (BEAM) and Madrigal Pharmaceuticals (MDGL)
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $42
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $37 to $75
Beam Therapeutics: Strong Pipeline and Strategic Global Expansion Justify Buy Rating
Bernstein Upgrades Beam Therapeutics(BEAM.US) to Buy Rating, Raises Target Price to $37
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $42 to $80
Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Beam Therapeutics Analyst Ratings
Promising Early Data and Innovative Approaches Lead to Buy Rating for Beam Therapeutics
J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $48
Analysts' Top Healthcare Picks: Stoke Therapeutics (STOK), Beam Therapeutics (BEAM)
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating
William Blair Remains a Buy on Beam Therapeutics (BEAM)
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
Beam Therapeutics Is Maintained at Sector Perform by RBC Capital
Scotiabank Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Cuts Target Price to $24
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $31 to $69
Beam Therapeutics Analyst Ratings
JonesTrading Sticks to Their Hold Rating for Beam Therapeutics (BEAM)